Skip to content

Welcome to Discover Pharma! Today is : October 12, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

age-related macular degeneration

  • Advanced Therapies,Biotech & Pharma Business,Pharmaceuticals and therapeutics,Research & Development

    Eleva separates biologics platform from Factor H therapy

    Eleva is separating its moss-based biologics platform from its clinical-stage [...]

    September 15, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Age-related macular degeneration market across 7MM forecast to reach $20.5 billion by 2034

    The age-related macular degeneration market across the seven major markets [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Complement Therapeutics receives FDA IND clearance for CTx001 to enter Opti-GAIN trial in geographic atrophy

    Complement Therapeutics GmbH (CTx) has received clearance from the FDA [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Merck highlights RDKit’s role in AI-driven drug discovery
    Categories: Biotech & Pharma Business, Digital & Data, Drug Discovery & Development, Research & Development
  • Novadip secures €10.4M to advance pivotal Phase 3 trial
    Categories: Advanced Therapies, Biotech & Pharma Business, Clinical & Regulatory, Research & Development, Therapeutic Areas
  • Telix to acquire ITM in $1.65BN radiopharmaceutical deal
    Categories: Biotech & Pharma Business, Manufacturing & Supply Chain, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top